NCT02576795View on ClinicalTrials.gov

Gene Therapy Study in Severe Haemophilia A Patients (270-201)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 28, 2015

Primary Completion Date

February 14, 2024

Study Completion Date

February 14, 2024

Conditions
Severe Haemophilia A
Interventions
BIOLOGICAL

valoctocogene roxaparvovec

Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A

Trial Locations (5)

Unknown

Queen Elizabeth Hospital Birmingham, Birmingham

Addenbrooke's Hospital, Cambridge

St. Thomas' Hospital, London

The Royal London Hospital, London

University Hospital Southampton NHS Foundation Trust, Southampton

Sponsors
All Listed Sponsors
lead

BioMarin Pharmaceutical

INDUSTRY